Decks Cleared For Mylan-Agila Deal But More Headwinds In Sight On Foreign Buyouts
This article was originally published in PharmAsia News
A six-month drama over the $1.6 billion Mylan-Agila deal has ended as India’s prime minister intervened amid inter-departmental conflicts. However buyouts will not be any easier for multinational companies as new rules are being worked out for tighter controls.
You may also be interested in...
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry
MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.